Webinar: Clinical value of cystatin C in drug dosing

24. Feb 2021 | 5 min read

Webinar: Clinical value of cystatin C in drug dosing

Clinical value of predicting renal elimination of medications with cystatin C

Welcome to the fourth webinar in Gentian's cystatin C webinar series. Our US Product Specialist, Shanyil Wickramasinghe, will focus on two real-world scenarios to illustrate the clinical value of incorporating cystatin C testing into medication dosing and monitoring protocols:

  • Personalising chemotherapeutic interventions through co-reporting of cystatin C and creatinine-based eGFRs

  • Cystatin C-guided dosing of vancomycin: A novel approach to achieving trough concentrations among ICU patients

Data presented in this webinar is collected from publications of independent research1-10.

 

Watch the webinar here: 

Watch webinar here

Contact Gentian - Cystatin C

Get in touch with our Product Manager for cystatin C for product specification and pricing:

 

 

 

References:

  1. McMahon, BA and MH Rosner. GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer, in Kidney360, 2020. 
  2. Santos, MLC et al. Nephrotoxicity in cancer treatment: An overview, in World J Clin Oncol, 2020. 
  3. Orth, M et al. Avoiding Insufficient Therapies and Overdosing with Co-Reporting eGFRs for Personalized Drug Therapy and Improved Outcomes, in ACHIEVING MEASURABLY BETTER HEALTHCARE PERFORMANCE, 2019.
  4. Frazee, EN et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study, in Crit Care, 2014. 
  5. Begg, EJ, ML Barclay and CJ Kirkpatrick. The therapeutic monitoring of antimicrobial agents, in Br J Clin Pharmacol, 1999. 
  6. Levine, DP. Vancomycin: a history, in Clin Infect Dis, 2006. 
  7. FDA, Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing, DHHS, Editor. 2020: www.fda.gov.
  8. Frazee, E et al. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project, in Am J Kidney Dis, 2017.
  9. Kullar, R et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort, in Pharmacotherapy, 2012. 
  10. Lloyd-Smith, P et al. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay, in J Hosp Infect, 2013. 

You may also read


Production assistant - HQ based in Moss, Norway

May 13, 2024

Production assistant - HQ based in Moss, Norway

Would you like to contribute to our ability to meet the internationally increasing demand for our products?..

Application Sales Specialist (US based) 

May 13, 2024

Application Sales Specialist (US based) 

Join Gentian: Application Sales Specialist (US based) We are looking for a new colleague in the position of..

Discussing cystatin C @ Spring Clinical Meetings 2024

May 08, 2024

Discussing cystatin C @ Spring Clinical Meetings 2024

Spring Clinical Meetings (SCM) is a great occasion for renal health care providers to get insights to..